Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target: Broad ORGS Patent for Turning Liver Cells into Insulin Producing Cells Creates a Potential Cure for Diabetes
Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target
Orgenesis (ORGS) is a $35 million market cap biotechnology company that is committed to curing Type 1 Diabetes with a novel technology that combines cellular therapy and regenerative medicine.
Pall Corporation (PLL) is a $10 billon market cap company with a focus on manufacturing of cell therapies.
"Orgenesis has an exciting approach to Diabetes research with its 'cellular trans-differentiation,' a technology that has potential to regenerate glucose-responsive insulin production in patients," said Mario Philips, President single-use technology at Pall. "We believe this has the potential of providing a cure for Type 1 Diabetes and other insulin-dependent disorders. This program will combine two of our leading technologies to provide a complete commercial-scale manufacturing solution."
Through a proprietary biologic process called "cellular trans-differentiation," Orgenesis has proven that, when exposed ex vivo (i.e., outside the body) to certain pancreatic transcription factors and in specific sequence, human adult liver cells can be transformed into fully functional, beta cell-like insulin producing cells (IPCs).
These IPCs are re-infused into the body via the portal vein. In pre-clinical models of Type 1 Diabetes (Non-Obese Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond to glucose challenge and successfully maintain glycemic homeostasis.
In the same NOD model, the implanted IPCs were not subject to auto-immune attack or cellular ablation which is the KEY problem with the existing pancreatic islet cell transplantation treatment.
Orgenesis plans to initiate Phase 1/2 trials in the next 12-16 months. For more information visit: www.orgenesis.com .
To learn more about ORGS, check out our initial report.
http://finance.yahoo.com/news/orgenesis-pall-corporation-receive-800-134827506.html
Founder and Editor-in-Chief for NBTEquitiesResearch.com. Contributor and Anchor for the Fox News Channel and Fox Business Network 2000-2013. Chairman & CEO of NBT Group, Inc., a boutique private capital investment bank and investor relations organization.
- Login to post comments
